Zacks Research Has Positive Forecast for BDX Q3 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Equities researchers at Zacks Research upped their Q3 2026 earnings estimates for shares of Becton, Dickinson and Company in a research note issued on Tuesday, January 21st. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $4.02 per share for the quarter, up from their previous estimate of $4.01. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.42 per share.

Several other equities analysts have also recently issued reports on BDX. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI boosted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and an average price target of $283.50.

Becton, Dickinson and Company Stock Performance

BDX opened at $240.21 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The firm has a fifty day moving average price of $227.44 and a 200 day moving average price of $232.83. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $248.42. The stock has a market cap of $69.66 billion, a P/E ratio of 40.44, a P/E/G ratio of 1.74 and a beta of 0.39.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the previous year, the business posted $3.42 EPS. The business’s revenue was up 6.9% compared to the same quarter last year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were given a dividend of $1.04 per share. The ex-dividend date was Monday, December 9th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a yield of 1.73%. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP David Shan sold 500 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the sale, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Shana Carol Neal sold 788 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the sale, the executive vice president now directly owns 16,201 shares of the company’s stock, valued at $3,807,235. The trade was a 4.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 9,844 shares of company stock valued at $2,210,716 over the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

A number of hedge funds have recently modified their holdings of BDX. Livelsberger Financial Advisory purchased a new stake in shares of Becton, Dickinson and Company in the third quarter valued at about $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of Becton, Dickinson and Company in the third quarter valued at about $33,000. Tompkins Financial Corp grew its holdings in shares of Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the period. Sound Income Strategies LLC grew its holdings in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Finally, Kennebec Savings Bank purchased a new stake in shares of Becton, Dickinson and Company in the third quarter valued at about $46,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.